scispace - formally typeset
W

William E. Van Nostrand

Researcher at University of Rhode Island

Publications -  119
Citations -  7873

William E. Van Nostrand is an academic researcher from University of Rhode Island. The author has contributed to research in topics: Cerebral amyloid angiopathy & Amyloid. The author has an hindex of 42, co-authored 109 publications receiving 7056 citations. Previous affiliations of William E. Van Nostrand include Stony Brook University & University of California, Irvine.

Papers
More filters
Journal ArticleDOI

Structural conversion of neurotoxic amyloid-[beta]1-42 oligomers to fibrils

TL;DR: It is shown that low-temperature and low-salt conditions can stabilize disc-shaped oligomers (pentamers) that are substantially more toxic to mouse cortical neurons than protofibrils and fibrils, and that these neurotoxic oligomers do not have the β-sheet structure characteristic of fibril.
Journal ArticleDOI

Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD

TL;DR: The findings confirmed that treatment of microglia with anti-inflammatory cytokines such as IL-4 and IL-13 induces a gene profile typical of alternative activation similar to that previously observed in peripheral macrophages and suggest that innate immune cells in AD may exhibit a hybrid activation state that includes characteristics of classical and alternative activation.
Journal ArticleDOI

Early-onset and Robust Cerebral Microvascular Accumulation of Amyloid β-Protein in Transgenic Mice Expressing Low Levels of a Vasculotropic Dutch/Iowa Mutant Form of Amyloid β-Protein Precursor

TL;DR: It is shown that overexpression of human AβPP is not required for early-onset and robust accumulation of both vascular and parenchymal Aβ in mouse brain, and in vivo transport studies demonstrated that Dutch/Iowa mutant Aβ was more readily retained in the brain compared with wild-type Aβ.
Journal ArticleDOI

Pathogenic Effects of D23N Iowa Mutant Amyloid β-Protein

TL;DR: Whereas the A21G Flemish mutation appears to enhance Aβ production, the E22Q Dutch and D23N Iowa mutations enhance fibrillogenesis and the pathogenicity of Aβ toward HCSM cells, suggesting that the different CAA mutations in AβPP may exert their pathogenic effects through different mechanisms.